CanaQuest Medical Corporation · OTC:CANQF
CanaQuest Medical — Investor Presentation (January 2021)
19 slides from CanaQuest Medical's investor presentation, January 2021
Slide 1: Corporate Introduction
Corporate Introduction January 2021
Slide 2: CanaQuest Medical Corp Vision
CanaQuest Medical Corp LIFE SCIENCE/PHARMACEUTICAL COMPANY VISION To be a global leader in the formulation and development of health products from cannabis derivatives. C O N F I D E N T I A L & P R O P R I E TA R Y 2
Slide 3: Problem | No Science Behind Medical Cannabis Products
Problem | No Science Behind “Medical” Cannabis Products Today’s “medical” cannabis products take a trial-and-error approach to treating symptoms, rather than following a scientific method. CBD by itself, is not effective for mental health - does not cross the Blood Brain Barrier (BBB) ❑ Cannabis sol
Slide 4: Opportunities | Revenue Stream Even Before FDA approval
Opportunities | Revenue Stream Even Before FDA approval Pharmaceutical Full pharmaceutical (Rx) product with FDA-certified healthcare claims (FDA approval required): Mentanine Rx Mentabinol Rx ❑ Dravet syndrome ❑ Multiple Sclerosis (MS) ❑ Lennox Gastaut syndrome ❑ Spasticity ❑ Tuberous Sclerosis Com
Slide 5: Corporate Advantages | What Sets Us Apart From The Competition
Corporate Advantages | What Sets Us Apart From The Competition End-to-End Scientific Approach Low Overhead & Near-Term Revenue ❑ Western University & Dr. Steven Laviolette, as industry ❑ Management & insiders hold 49% of shares outstanding partners since 2017 on a fully diluted basis ❑ CanaQuest own
Slide 6: Pharmaceutical Product | Comparison with Similar, FDA Approved Product
Pharmaceutical Product | Comparison with Similar, FDA Approved Product Mentanine®Rx US$650/100ml1 Epidiolex® Rx US$1,300/100ml Scientifically developed medicinal formula FDA-approved for epilepsy2 CBD 22.2 mg /ml, with Omega-3 active ingredients, flavor w/o sweetener CBD 100mg /ml, sesame as a carri
Slide 7: Competitive Advantage | Science Behind the Product
Competitive Advantage | Science Behind the Product Mentanine® Rx & Bypassing digestive Mentabinol® Rx system (nano emulsified) Delivered sublingually Other CBD & THC Damaging digestive (non nano emulsified) Delivered orally system C O N F I D E N T I A L & P R O P R I E TA R Y 7
Slide 8: Steps To FDA Approval
Steps To FDA Approval | Similar To Process With Health Canada Completed pre-clinical trials & Patented Master Formulations Advanced discussions with BioPharma Global, engagement as consultants expected shortly after completion of financing Seek Orphan Drug status (Dravet Syndrome, Lennox-Gastaut Syn
Slide 9: ADC BioMedical Corp | Source of Near-Term Revenue
ADC BioMedical Corp | Source of Near-Term Revenue Mentanine® Sublingually applied with a Mentabinol® Sublingually delivered powder (Omega-3 + CBD) spray bottle (THC + L-Theanine) Omega-3 L- Theanine Compounds R E S U LT S 20mg of Mentanine® = 10× activation R E S U LT S 1mg of Mentabinol® = 10× effi
Slide 10: Mentanine | Is Not The CBD Oil Currently Sold In The Market
Mentanine® | Is Not The CBD Oil Currently Sold In The Market Mentanine® CBD + carrier oil (Omega-3 + CBD) (coconut, grapeseed, sesame… ) Omega-3 Stops At CB-2 Compounds Carrier oil Receptor Crosses BBB - Fast R E S U LT S 20mg of Mentanine® = 10× More effective1 R E S U LT S 200mg of CBD intake = 10
Slide 11: Roadmap 2021 | Near-Term Strategy After Completion Of Financing
Roadmap 2021 | Near-Term Strategy After Completion Of Financing 0-60 days 60-90 days 90-150 days 150-180 days Mentanine® Mentanine® Mentanine® Mentanine® & Mentabinol® • E-commerce store launch • Establish human trials for • Inflammation (under Cannabis Act in epilepsy in Canada • Pain Management •
Slide 12: Milestones And Associated Costs Of Reaching Them
Milestones | And Associated Costs Of Reaching Them • List on Canadian Stock Exchange • FDA submission for Mentanine Rx (legal & audit) (orphan drug status, 505(b)(2) • Revenue from e-commerce site regulatory pathway, breakthrough • Worldwide revenue from (US) therapy designation) Mentanine Rx, Menta
Slide 13: Markets | Patients Suffering from TSC, Dravet & Lennox Gastaut Syndrome
Markets | Patients Suffering from TSC, Dravet & Lennox Gastaut Syndrome (After FDA Approval) Total Addressable Market ~ 1.1M patients worldwide Serviceable Addressable Market 158,330 patients in US, Canada & EU Serviceable Obtainable Market $780M revenue / year Based on: • 25% market share1 • $20,00
Slide 14: Markets | Significant Potential For Near-Term Revenue In CBD & Mental Health
Markets | Significant Potential For Near-Term Revenue In CBD & Mental Health Markets $335M Estimated size of the CBD market in Canada in 20211 $1.6B Estimated size of the CBD market in the US in 20212 However, the actual problem CanaQuest is addressing is far larger: $37B Estimated economic cost fro
Slide 15: GW Pharmaceuticals | Now & At Similar Stage of Development
GW Pharmaceuticals | Now & At Similar Stage of Development • GW Pharma (NASDAQ: GWPH) is the first company to have a CBD medication approved by the FDA • Pre-clinical trials have shown that Mentanine Rx has equal efficacy as GW Pharma’s Epidiolex at ~10x lower dosage, as it goes through the BBB (Epi
Slide 16: CanaQuest - Market Capitalization - Comparable Companies
CANAQUEST - MARKET CAPITALIZATION - COMPARABLE COMPANIES Share Price Shares Market Company Name Pre-Revenue Profitable Symbol Market 05-Jan-21 Outstanding Capitalization 1.) GW Pharmaceuticals, PLC No No GWPH NASDAQ $ 9.94 374,169,836 $ 3,718,312,745 2.) Charlotte's Web Holdings Inc No No CWBHF OTCQ
Slide 17: Management Team
Management Team | 150+ Years of Management & Product Development Experience Ross Eastley, CA Richard Rusiniak, Mechanical Engineer CFO, Director CEO, Director Over 30 years of accounting and CFO experience in both private and public sector Over 30 years of management, design and process experience.
Slide 18: Scientific Team | Building a Future Based On Science
Scientific Team | Building a Future Based On Science BY THE NUMBERS ADVISORY TEAM IN PROCESS Remi A Menes, BSc, MBA Chairman, Advisory Committees 14 Julia Ghavami SCIENTISTS Marketing Director, California, USA Cheri Shafer, Clinical Mgr. 75,000 Physician, Patient Acquisition & H E A LT H Education,
Slide 19: Contact Information
OTC Pink: CANQF Contact Information: Paul Ramsay, President 416.704.3040 [email protected] www.canaquest.com 19
CanaQuest Medical — Investor Presentation (January 2021) on 6ix